SUSCA, SARA
 Distribuzione geografica
Continente #
NA - Nord America 175
EU - Europa 81
AS - Asia 45
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
SA - Sud America 1
Totale 304
Nazione #
US - Stati Uniti d'America 174
IT - Italia 43
SG - Singapore 30
IE - Irlanda 14
SE - Svezia 8
CN - Cina 7
FI - Finlandia 5
FR - Francia 3
GB - Regno Unito 3
IN - India 3
ID - Indonesia 2
VN - Vietnam 2
BR - Brasile 1
CA - Canada 1
ES - Italia 1
EU - Europa 1
GR - Grecia 1
JP - Giappone 1
MK - Macedonia 1
NL - Olanda 1
NZ - Nuova Zelanda 1
UA - Ucraina 1
Totale 304
Città #
Chandler 34
Singapore 26
Ann Arbor 16
Dublin 14
Ashburn 10
Catania 6
Turin 6
Lappeenranta 5
Medford 4
Milan 4
New York 4
Nyköping 4
Princeton 4
Santa Clara 4
Washington 4
Torino 3
Urbino 3
Bandung 2
Boston 2
Falls Church 2
Florence 2
Guiyang 2
Hebei 2
Modena 2
Naples 2
Nottingham 2
Rome 2
Arcene 1
Auckland 1
Barcelona 1
Beijing 1
Bourne 1
Chengdu 1
Chioggia 1
Greenville 1
Grugliasco 1
Hangzhou 1
Hyderabad 1
Jacksonville 1
Kansas City 1
Katihar 1
Mountain View 1
Mumbai 1
Nijmegen 1
Norwalk 1
Philadelphia 1
Piraeus 1
Regina 1
Riverton 1
Sandston 1
Seattle 1
São Paulo 1
Wilmington 1
Totale 197
Nome #
Dual-targeted therapy with apremilast and vedolizumab in pyoderma gangrenosum associated with Crohn’s disease 62
Comparison of Secukinumab and Ixekizumab in psoriasis: a real-life cohort study on the efficacy and drug survival of 445 patients 53
Risankizumab shows high efficacy and maintenance in improvement of response until week 52 40
A new suture technique for flap closure in dermatologic surgery 23
Drug survival and efficacy of anti-interleukin 23 biologics in psoriasis: a comparative study on different agents 20
Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients 19
Brodalumab efficacy in bio-naïve psoriasis patients: real-life experience of 202 subjects up to 48 weeks 16
Oral doxycycline in HIV-related synchronous malignant syphilis and condyloma lata 16
Effectiveness of Brodalumab on Scalp, Palmoplantar, and Genital Psoriasis: A Descriptive Pilot Study 15
"Superresponders" at biologic treatment for psoriasis: A comparative study among IL17 and IL23 inhibitors 14
Tildrakizumab in real-life shows good efficacy in moderate-to-severe psoriasis regardless of previous use of biologic drugs and joint involvement 12
Risankizumab shows faster response in bio naïve than in bio-experienced psoriatic patients 12
Mask-related acne flares during the COVID era 9
Comparison between brodalumab, secukinumab and ixekizumab effectiveness and drug survival: A real-life experience on 638 patients with psoriasis 6
Anti-IL23 in inflammatory bowel disease patients with dermatological indication: The shared gastroenterological-dermatological clinic experience 5
Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment 3
Drug survival und klinische Wirksamkeit von Secukinumab, Ixekizumab, Brodalumab, Guselkumab, Risankizumab und Tildrakizumab in der Behandlung der Psoriasis: Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment 3
Totale 328
Categoria #
all - tutte 2.438
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.438


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204 0 0 0 0 0 0 0 0 0 0 0 4
2020/202110 3 2 2 1 0 0 0 0 0 0 0 2
2021/202254 3 0 1 1 4 0 7 6 3 3 9 17
2022/2023110 6 9 3 3 9 20 6 21 13 0 12 8
2023/2024124 10 22 10 11 3 12 8 4 2 13 10 19
2024/202526 3 23 0 0 0 0 0 0 0 0 0 0
Totale 328